Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the second tranche (the "Second Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to
2026-03-13 5:05 PM EDT | Sharp Therapeutics Corp.
BioHarvest Sciences Announces Grant of Long-Term Incentive Awards to Employees, Officers and Directors
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that its Board of Directors has approved the grant of long-term incentive ("LTI") awards to employees, officers and directors under the Company's equity incentive plan. These
Biotechnology, Pharmaceuticals, Health
2026-03-13 4:53 PM EDT | BioHarvest Sciences Inc.
iSpecimen Launches AI Agent Revolutionizing Biospecimen Matching
Woburn, Massachusetts--(Newsfile Corp. - March 12, 2026) - iSpecimen Inc. (NASDAQ: ISPC) (the "Company"), a leading technology marketplace connecting researchers with biospecimen suppliers, today announced the launch of its new AI-powered Inventory Agent, a purpose-built tool designed to help accelerate the process of reviewing incoming biospecimen requests and matching them with available inventory across its global supplier network. The internally developed AI
2026-03-12 4:05 PM EDT | iSpecimen Inc.
BioGene Therapeutics Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director
Vancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"), a company that it is a significant shareholder of, has appointed Raj S. Pruthi, MD, MHA, FACS, as a Director of the Company.
Biotechnology, Pharmaceuticals, Health
2026-03-12 3:00 AM EDT | PreveCeutical Medical Inc.
Bachem Reports Strong Sales Growth and Sustained High Profitability
Bubendorf, Switzerland--(Newsfile Corp. - March 12, 2026) - Ad hoc announcement pursuant to Art. 53 LR Bachem Reports Strong Sales Growth and Sustained High Profitability Group sales increase to CHF 695.1 million in 2025 (+14.8%, in local currencies +19.2%). EBITDA increases to CHF 214.7 million (+21.8%, in local currencies +32.6%). EBITDA margin lies at 30.9%. Adjusted for one-time effects of CHF 16.1 milli
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2026-03-12 1:59 AM EDT | Bachem Holding AG
Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents
Toronto, Ontario--(Newsfile Corp. - March 11, 2026) - Younet.ai, a Toronto-based AI technology company specializing in enterprise-grade private LLM solutions, today announced that the recent release of AutoResearch by AI pioneer Andrej Karpathy provides strong external validation for the autonomous research-agent approach underpinning Researgency.ai, Younet's agentic research platform being developed in collaboration with Kala Bio, Inc. (NASDAQ: KALA). AutoResearch is an open-source too
Technology, Biotechnology, Computer Software
2026-03-11 11:18 AM EDT | Younet.ai
Envoy Medical Completes Enrollment of Pivotal Clinical Trial Evaluating First-Of-Its-Kind Fully Implanted Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - March 11, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced completed enrollment of its pivotal clinical trial for the investigational fully implanted Acclaim® cochlear implant. With the successful implantation of the 56th and final patient, Envoy Medical is the first cochlear implant company to achieve full enro
Biotechnology, Healthcare and Hospitals
2026-03-11 8:00 AM EDT | Envoy Medical, Inc.
Restart Life Highlights Certified Manufacturing Platform to Drive Margin Expansion and Distribution Growth
Vancouver, British Columbia--(Newsfile Corp. - March 11, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide investors with an update on the strategic value of the Holy Crap™ manufacturing facility and its role in supporting scalable growth, margin expansion, and broader market distribution across the Company's functional wellness portfolio. The Holy Crap™ production facility operates under mul
Technology, Biotechnology, Health
2026-03-11 8:00 AM EDT | Restart Life Sciences Corp.
TempraMed's Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap
Vancouver, British Columbia--(Newsfile Corp. - March 11, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the publication of a clinical case report evaluating the use of VIVI Cap™ for passive thermal protection of insulin during summer travel. The paper, titled "Passive Thermal Protection
Technology, Biotechnology, Pharmaceuticals, Health
2026-03-11 7:00 AM EDT | TempraMed Technologies Ltd.
Theralase(R) Closes $1.1 M Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-03-10 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
King of Prussia, Pennsylvania--(Newsfile Corp. - March 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-10 7:00 AM EDT | Phio Pharmaceuticals Corp.
Hemostemix Leadership Attending Abundance360 Summit
Calgary, Alberta--(Newsfile Corp. - March 9, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced that Thomas Smeenk CEO and Peter Lacey, Chairman are attending the 2026 Abundance360 Summit in Los Angeles this week. Founded by futurist and entrepreneur Peter H. Diamandis, the annual Abundance360 Summit convenes leading entrepreneurs, and investors, working at the frontiers of biotechnology, artificial intelligence, longevity science, and other exponential techn
Biotechnology, Pharmaceuticals, Health
2026-03-09 11:23 AM EDT | Hemostemix Inc.
OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting
New York, New York--(Newsfile Corp. - March 9, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today provided an update regard
2026-03-09 7:40 AM EDT | OS Therapies
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small
Biotechnology, Pharmaceuticals
2026-03-09 7:30 AM EDT | InMed Pharmaceuticals
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to present its latest preclinical data demonstrating that X-Ray-activated Rutherrin® is effective in th
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-03-09 7:00 AM EDT | Theralase Technologies Inc.
Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement offering (the "Offering") of non-transferable secured convertib
2026-03-09 7:00 AM EDT | Telo Genomics Corp.
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Montreal, Quebec--(Newsfile Corp. - March 9, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the closing of a private placement (the "Private Placement") of 17,445,455 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of $9,595,000.25. Each Unit is comprised
Biotechnology, Pharmaceuticals, Health
2026-03-09 3:15 AM EDT | Defence Therapeutics Inc.
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1/CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned subsidiary of the Company, in light of ongoing uncertainty surrounding U.S. federal legislation. As previously annou
Biotechnology, Pharmaceuticals
2026-03-06 5:04 PM EST | InMed Pharmaceuticals
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeuti
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-05 4:05 PM EST | Phio Pharmaceuticals Corp.
BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi Levy
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 5, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology, today announced that Mr. David Tsur will step down from its Board of Directors after more than four years of service. The Company further announced the appointment of Prof. Hezi Levy to its Board of Directors, effective immediately. Mr. Tsur has served on BioHarvest's Board since 2021 and
Biotechnology, Pharmaceuticals, Health
2026-03-05 7:30 AM EST | BioHarvest Sciences Inc.